The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated.

The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents.

According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.

Based on monotherapy data from an open-label, multi-center, single-arm study of 105 adults with platinum-sensitive and platinum-resistant SCLC that progressed after platinum-based chemotherapy, the FDA granted accelerated approval to lurbinectedin (Zepzelca; Jazz Pharmaceuticals and PharmaMar).

Published in Practical Radiation Oncology, the recommendations from the American Society for Radiation Oncology (ASTRO) are based on a systematic literature review, consensus, and system for grading evidence quality and recommendation strength.

As a result of COVID-19, many physicians had to provide telemedicine services in a matter of weeks, if not days. A major accomplishment, for sure. But are you getting paid for your hard work? Read on to find out how you can ensure you are being compensated for the work you’ve been doing.